medigraphic.com

2004, Number 1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2004; 42 (1)

Experience in treatment of myocadial infarction in the intensive care unit

Salazar WE

Language: Spanish
References: 33
Page: 61-67
PDF size: 67.03 Kb.


ABSTRACT

We carried out a revision of 305 records of patients with acute myocardial infarction treated with three different drugs. We analyzed effectiveness of each on decreasing complications and mortality. Clinical diagnosis was confirmed by electrocardiogram and laboratory test of creatininekinase and MB isoenzyme. We used Killip and Kimbal class to stratify infarction and number of leads affected with segment ST elevation to assess size. We observed better evolution in patients treated with streptokinase because they showed fast decrease of angor pain and ST segment elevation. However, these patients had bleeding, arterial hypotension, and other complications. Unfractionated heparin showed low effectiveness due to shortage of effects in coronary thrombus; these patients underwent major, long-term bleeding complications with angor pain. This group had highest mortality. Enoxaparin showed better effectiveness due to antithrombotic activity and some thrombolytic capacity allowed better patient evolution, decreasing complications and mortality.


REFERENCES

  1. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847- 860.

  2. Thompson CA, Danzell JD, Hanley HG. Advances in the pathogenesis and treatment of acute coronary syndromes. J LA State Med Soc 1999;151(5):272- 277.

  3. Zaaks SM, Liebson PR, Calvin JE. Unstable angina and non Q wave myocardial infarction: Does the clinical diagnosis have therapeutic implications? J Am Coll Cardiol 1999:33.

  4. Wallentin L, Ohlsson J, Swahn E, Karlson E, Lundin L, Landgren F, Saetre H. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996;347(9001):561-568.

  5. Stone GW. Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes. Am J Cardiol 1999;83(9A):16E-20E.

  6. Mark DB, Cowper PA, Berdowitz SD, Davidson RL, Turpie AG, Califf RM, Cohen M. Economic assessment of low molecular heparin versus unfractionated heparin in acute coronary syndrome patients. Circulation 1998;97(17):1702-1707.

  7. Califf RM, Newby LK. How much do we gain by reducing time to reperfusion therapy. Am J Cardiol 1996;78:8-15.

  8. Smalling RW. Molecular biology plasminogen activators. Am J Cardiol 1996;78 (Suppl 12A):2-7.

  9. White HD, Barbash GI, Califf RM, Simes RJ, Granger CV. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO 1 Trial. Circulation 1996;94(8):1826-1833.

  10. Wilcox GR. Clinical trials in thrombolytic therapy. What do they tell us? INJECT 6 months outcomes data. Am J Cardiol 1996;78(Suppl 21A):20-23.

  11. Choy JB, Armnstrong PW. Anticoagulant therapy in unstable angina. Cardiol Clin 1999;17(2):327-343.

  12. Xiao Z, Theorux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with a low molecular weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97(3):251-256.

  13. Turpie AG. Anticoagulants in acute coronaries syndromes. Am J Cardiol 1999;84(5A):2M-6M.

  14. Zed PJ, Tisdale JE, Borzak S. Low molecular weight heparins in the management of acute coronary syndromes. Arch Intern Med 1999;159 (16):1849-1857.

  15. Purcell H, Fox KM. Current roles and future possibilities of low molecular weight heparins in unstable angina. Eur Heart J 1998;19(Suppl):18-23.

  16. Ocampo S, Solorio S, Rangel A, Madrid F, Romero MA, Carrillo AM. La heparina de bajo peso molecular en la angina de pecho inestable. Arch Inst Cardiol Mex 1999;69:222-227.

  17. Cohen M. Low molecular weight heparins in the management of unstable angina/non Q wave myocardial infarction. Semin Thromb Hemost 1999;25(Suppl 3):113-121.

  18. Braunwald E, Antman EM, McCabe CH, Marble SJ, Canon CP. Dose ranging trial of enoxaparin for unstable angina: Results of TIMI IIA. J Am Coll Cardiol 1997;26(7):1474-1482.

  19. Antman EM, McCabe CH, Gurfinkel EP, Lablanche JM. Enoxaparin prevents death and cardiac ischemic events in unstable angina non Q wave myocardial infarction. Circulation 1999;100(15):1593-1601.

  20. Mair F. Clinic applications of thrombolytic therapy. Am Fam Physician 1996;54:2041-2048.

  21. Smalling RW. Controversies in thrombolytic therapy. Am J Cardiol 1996;78(Suppl 21A):101-104.

  22. Silver SH, Leo PJ, Katapadi M. Serial electrocardiograms for chest pain in patients with initial nondiagnostic electrocardiograms: implications for thrombolytic therapy. Acad Emerg Med 1996;3(2): 142-152.

  23. Quigley RL, Khandekar MN, Switzer SS, Salnger MH. Immediate hemodynamic effects of thrombolytic therapy on the ischemic myocardium. Catheter Cardiovasc Diagn 1996;38(3):325-330.

  24. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.

  25. Kucharoya L, Cagan S. The electrocardiogram in acute myocardial infarction in the thrombolyticera. Bratils Lek Lesty 1996;97(7):138-146.

  26. Salazar WE. Tratamiento trombolítico en el infarto del miocardio. Rev Med IMSS 1998;36(5):345-348.

  27. Futterman LG, Lemberg L. Low molecular weight heparin: an antithrombotic agent whose time has come. Am J Crit Care 1999;8(1):520-523.

  28. Salazar WE. Enoxaparina y heparina no fraccionada en infarto del miocardio no trombolisado. Rev Med IMSS 2001;39(3):207-213.

  29. Ridgway PF, Crosbie J, Hinedi KA, Gladban W. Unfractionated heparin, time for a change? Ir Med J 1999;92(3):302-306.

  30. Armstrong PW. Heparin in acute coronary disease. Requiem for a heavy weigth? N Engl J Med 1997; 337(7):492- 494.

  31. Goodman SG, Cohen M, Bigonzi F, Gutfinkel EP, Radley DR. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one year results of the ESSENCE study. J Am Coll Cardiol 2000;36:693-698.

  32. Antman EM, Cohen M, Bogonzi F. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris non ST segment elevation acute myocardial infarction having subsecuent percutaneous coronary intervention. Am J Cardiol 2002; 90:447-482.

  33. Antman EM. TIMI IIB. Enoxaparin versus unfractionated heparin for unstable angina or non Q wave myocardial infarction: a double-blind, placebocontrolled, parallel group, multicenter trial. Am Heart J 1998;135(6 Pt 3 Suppl):353-360.




2020     |     www.medigraphic.com